European Surveillance System on Contact Allergies (<scp>ESSCA</scp>): results with the European baseline series, 2013/14Wolfgang Uter, Mark Wilkinson, T. Kmecl et al.|Journal of the European Academy of Dermatology and Venereology|2017Cited by 124
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Antonio Costanzo, Giovanni Pellacani et al.|Frontiers in Medicine|2023Cited by 55
Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis)Diego Orsini, Antonio Costanzo, Giovanni Pellacani et al.|Dermatology Practical & Conceptual|2024Cited by 34
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Alessandra Narcisi, Diego Orsini et al.|Journal of Dermatological Treatment|2024Cited by 21
Metabolic Syndrome and Psoriasis: Pivotal Roles of Chronic Inflammation and Gut MicrobiotaPaola Secchiero, Anna Balato, Erika Rimondi et al.|International Journal of Molecular Sciences|2024Cited by 19